Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

An update on tetracyclines.

David M Shlaes1

  • 1Anti-Infectives Consulting, Stonington, CT 06378, USA. shlaes.david@earthlink.net

Current Opinion in Investigational Drugs (London, England : 2000)
|February 28, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Innovation, Nontraditional Antibacterial Drugs, and Clinical Utility.

ACS infectious diseases·2021
Same author

Antibacterial Drugs: The Last Frontier.

ACS infectious diseases·2020
Same author

Personal View of the Antibiotic Value Proposition.

ACS infectious diseases·2020
Same author

Can Europe Pull It Together?

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2020
Same author

The Economic Conundrum for Antibacterial Drugs.

Antimicrobial agents and chemotherapy·2019
Same author

Antibiotics-From There to Where?: How the antibiotic miracle is threatened by resistance and a broken market and what we can do about it.

Pathogens & immunity·2019
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Tetracyclines, once widely used antibiotics, face resistance. New glycylcyclines, like tigecycline, have been developed to overcome these resistance mechanisms and restore antibiotic utility.

Area of Science:

  • Microbiology
  • Medicinal Chemistry
  • Pharmacology

Background:

  • Tetracyclines are a class of natural product antibiotics with broad clinical applications.
  • Widespread use in human medicine, agriculture, and animal feed has led to significant bacterial resistance.
  • This resistance has limited the clinical effectiveness of traditional tetracycline antibiotics.

Purpose of the Study:

  • To review the development of novel tetracycline derivatives.
  • To highlight compounds that evade common bacterial resistance mechanisms.
  • To discuss the potential of these new agents beyond antibacterial therapy.

Main Methods:

  • Review of scientific literature on tetracycline and glycylcycline development.
  • Analysis of mechanisms of bacterial resistance to tetracyclines.

Related Experiment Videos

  • Evaluation of compounds designed to circumvent resistance.

    • Main Results:

    • Identification of 9-glycylamido-tetracyclines (glycylcyclines) as a promising class of compounds.
    • Demonstration that glycylcyclines evade most known tetracycline resistance mechanisms.
    • Clinical approval of tigecycline, the first glycylcycline, signifies success.

    Conclusions:

    • Glycylcyclines represent a significant advancement in combating antibiotic resistance.
    • These novel compounds offer renewed therapeutic options against resistant bacterial infections.
    • Further research into related compounds may yield additional treatments.